We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
-2.58%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$63.5M
AUM Growth
-$8.12M
Cap. Flow
-$4.99M
Cap. Flow %
-7.86%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
1
Tvardi Therapeutics
TVRD
$24M
$48.8M 76.92%
99,113
– –
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$14.1M 22.27%
32,721
– –
SENS icon
3
Senseonics Holdings Inc
SENS
$254M
$509K 0.8%
7,980
– –
RCKT icon
4
Rocket Pharmaceuticals
RCKT
$358M
– –
-656,948
Closed -$4.99M

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Rho Capital Partners held 4 positions worth $63.5M, down 11% from $71.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners withdrew a net $4.99M in Q3 2017, closing 1 position. Its most notable exit was Rocket Pharmaceuticals, an estimated $4.99M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Rho Capital Partners fully exited Rocket Pharmaceuticals in Q3 2017, selling an estimated $4.99M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $63.5M portfolio in Q3 2017.
  • Rho Capital Partners opened 0 new positions and closed 1 in Q3 2017.
  • Rho Capital Partners's portfolio value fell 11% quarter-over-quarter to $63.5M.

Based on Rho Capital Partners's 13F filing for Q3 2017, filed 6 Nov 2017.